Recurrent gefitinib-induced interstitial lung disease.
Gefitinib, the epidermal growth factor receptor tyrosine kinase inhibitor, is effective for patients with non-small cell lung cancer. However, a serious adverse effect, interstitial lung disease (ILD), has been reported. The re-administration of gefitinib might be considered when there is no other choice of treatment and a therapeutic effect can be expected; however, there is no published data on the safety of restarting gefitinib after its discontinuation in cases suspected of having gefitinib-induced ILD. We report a case with recurrent gefitinib-induced ILD, which suggests that re-administration of gefitinib should be considered cautiously in patients who have previously developed gefitinib-induced ILD.
Suzuki
Masaru
M
First Department of Medicine, Hokkaido University School of Medicine, Sapporo. suzumasa@med.hokudai.ac.jp
Asahina
Hajime
H
Konishi
Jun
J
Yamazaki
Koichi
K
Nishimura
Masaharu
M
D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy; D000077156:Gefitinib; D006801:Humans; D008168:Lung / Q000000981:diagnostic imaging / Q000473:pathology; D017563:Lung Diseases, Interstitial / Q000139:chemically induced* / Q000175:diagnosis*; D008175:Lung Neoplasms / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D011799:Quinazolines / Q000009:adverse effects* / Q000627:therapeutic use; D012008:Recurrence; D014057:Tomography, X-Ray Computed
D000970:Antineoplastic Agents; D011799:Quinazolines; D000077156:Gefitinib